This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: JACC Cardiovascular Interventions
Author(s): Gabriele Crimi; Silvia Pica; Claudia Raineri; Ezio Bramucci; Gaetano M. De Ferrari; Catherine Klersy; Marco Ferlini; Barbara Marinoni; Alessandra Repetto; Maurizio Romeo; Vittorio Rosti; Margherita Massa; Arturo Raisaro; Sergio Leonardi; Paolo Rubartelli; Luigi Oltrona Visconti; Maurizio Ferrario

In this randomized trial involving 100 pts requiring PCI for STEMI and occluded LAD, half received lower extremity preconditioning for 3 cycles of 5min/5min ischemia/reperfusion. Preconditioning reduced enzymatic infarct size, reduced myocardial edema, and provided greater improvement in ST segment resolution.

Source: Journal of Clinical Oncology
Author(s): Kazuki Sudo, Takashi Taketa, Arlene M. Correa, Maria-Claudia Campagna, Ropma Wadhwa, Mariela A. Blum, Ritsuko Komaki, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Heath D. Skinner, Dipen M. Maru, David C. Rice, Stephen G. Swisher, Wayne L. Hofstetter, Jafar A. Ajani

This single institution restrospective review examined outcomes of treatment for loco-regional recurrence after definitive trimodality therapy (chemotherapy, radiation therapy, resection) for esophageal adenocarcinoma.  Isolated local recurrence developed in 27 patients (5%), most within 3 years.  Median overall survival of those with loco-regional recurrence was 17 mos, with a poor response to additional therapy.  These data suggest that intense post-treatment surveillance programs aimed at early detection of loco-regional recurrence may not provide much benefit. 

Source: Cancer Discovery
Author(s): Nadine S. Jahchan, Joel T. Dudley, Pawel K. Mazur, Natasha Flores, Dian Yang, Alec Palmerton, Anne-Flore Zmoos, Dedeepya Vaka, Kim Q.T. Tran, Margaret Zhou, Karolina Krasinska, Jonathan W. Riess, Joel W. Neal, Purvesh Khatri, Kwon S. Park, Atul J. Butte and Julien Sage

This study found that tricyclic antidepressants like Imipramine, used to treat major depression and Promethazine used as an antiemetic and antihistaminic, induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture,v and in mouse and human SCLC tumors transplanted into immunocompromised mice. The relevance of this work is based on the power of bioinformatics to find new drugs to treat SCLC. The authors used gene expression microarrays to know how expression levels change in SCLC compared to normal lung cells. They found a gene expression signature for SCLC by using publically available gene expression data from FDA-approved drugs. Tricyclic antidepressants had a similar signature to previous chemotherapy agents, which suggested their ability to antagonize SCLC growth.

Source: Journal of the American College of Cardiology
Author(s): Javariah Siddiqui, Christian P. Brizard, John C. Galati, Ajay J. Iyengar, Darren Hutchinson, Igor E. Konstantinov, Gavin R. Wheaton, James M. Ramsay, Yves d’Udekem

This interesting retrospective study compared the long-term results of surgical valvuloplasty and balloon valvuloplasty for congenital aortic stenosis in neonates and infants. During the study period, 86 patients underwent surgical valvuloplasty and 37 patients had a balloon valvuloplasty as first intervention. The two most important factors adversely related to long-term outcomes (including re-stenosis, re-intervention, and regurgitation) on multivariate analysis were having a balloon valvuloplasty as first procedure and undergoing initial treatment as a neonate. Freedom from reintervention at 10 years with surgery was 55% for neonates and 78% for infants. On the contrary, freedom from reintervention at 8 years with balloon valvuloplasty was 15% for neonates and 40% for infants. The authors concluded that despite the retrospective nature of this analysis (and the possibility of bias), surgical valvuloplasty is associated with better long-term outcomes than balloon valvuloplasty.

Source: Journal of the American College of Cardiology
Author(s): Ribeiro HB, Webb JG, Makkar RR, Cohen MG, Kapadia S, Kodali S, Tamburino C, Barbanti M, Chakravarty T, Jilaihawi H, Paradis JM, de Brito FS Jr, Cánovas SJ, Cheema AN, de Jaegere P, Valle RD, Chiam PT, Moreno R, Pradas G, Ruel M, Salgado-Fernández J, Sarmento-Leite R, Toeg H, Velianou JL, Zajarias A, Babaliaros V, Cura F, Dager AE, Manoharan G, Lerakis S, Pichard A, Radhakrishnan S, Perin MA, Dumont E, Larose E, Pasian SG, Nombela-Franco L, Urena M, Tuzcu EM, Leon MB, Amat-Santos IJ, Leipsic J, Rodés-Cabau J.

In this manuscript, the authors review 44 cases of coronary artery obstruction following TAVI from a registry of 6688 patients. This complication is rare but life threatening. A number of variables such as older age, female gender, previous CABG, the use of balloon expandable prosthesis, previous surgical bioprosthesis, left coronary ostia height, and sinus of Valsalva diameter appear to be related to this complication.

Source: Journal of the American College of Cardiology
Author(s): Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW.

This paper is an expert consensus on the new definition of relevant myocardial infarction following both PCI and CABG. In patients with normal baseline CK-MB, post-procedural MI is defined as a peak CK-MB rise, measured within 48 hours of the procedure, equal or greater  than 10-times the local laboratory upper limit of normal (ULN) or equal or greater than 5-times the local laboratory ULN with new pathologic Q-waves in more than 2 contiguous leads or new persistent LBBB, OR in the absence of CK-MB measurements and a normal baseline cTn, a cTn (I or T) level  rise, measured within 48 hours of the procedure, greater than 70-times the local laboratory ULN, or greater than 35-times the ULN with new pathologic Q-waves in more than 2 contiguous leads or new persistent LBBB.  

Source: World Journal for Pediatric and Congenital Heart Surgery
Author(s): John W. Brown, Parth M. Patel, Mark D. Rodefeld, and Mark W. Turrentine.

The pulmonary autograft aortic valve replacement (Ross AVR) has clear advantages in growing children below the teenage years. Some recent reports have questioned the durability of the Ross AVR in older children and young adults, particularly those who present with predominant aortic regurgitation and a dilated aortic root. Brown and associates review their experience with the Ross operation in 79 children and young adults between the age of 10 and 20, mean of 16.0 ± 2.7 years. Analysis of outcomes including mortality, early and late complications and the need for reoperation is presented, with comparison to non-Ross AVR patients of the same age group during the same time period. The impact of technical modifications to the Ross operation is also assessed.

Source: Circulation
Author(s): Gabor Toth, MD; Bernard De Bruyne, MD, PhD; Filip Casselman, MD, PhD; Frederic De Vroey, MD; Stylianos Pyxaras, MD; Luigi Di Serafino, MD, PhD; Frank Van Praet, MD; Carlos Van Mieghem, MD, PhD; Bernard Stockman, MD; William Wijns, MD, PhD; Ivan Degrieck, MD; Emanuele Barbato, MD, PhD

This is a very interesting retropsective cohort study that looks at patients that either did or did not have an FFR preoperatively. 

FFR for intermediate stenoses reduced the number of grafts required and increased the number of patients suitable for OFF pump surgery with no difference in clinical outcome measures. 

Source: Transfusion
Author(s): PLASMACARD Study Group

This cohort study looks at the Administration of FFP in bleeding patients after cardiac surgery. it finds no difference in mortality in the FFP group and the no FFP group 

Source: Journal of Cardiac Surgery
Author(s): Timotheos G. Kelpis M.D.*, Vassilios A. Economopoulos M.D., Nikolaos E. Nikoloudakis M.D., Antonis A. Pitsis M.D.

71-year-old male who underwent successful minimally invasive transapical aortic valve implantation to treat severe aortic stenosis, with simultaneous pulmonary resection for the treatment of lung cancer. At five-year follow-up the patient remains free of symptoms (NYHA I) and recurrence.